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Background: Hemorrhage continues to be a leading cause of maternal death in developing countries. The 2012
World Health Organization guidelines for the prevention and management of postpartum hemorrhage (PPH)
recommend oral administration of misoprostol by community health workers (CHWs). However, there are several
outstanding questions about distribution of misoprostol for PPH prevention at home births.
Methods: We conducted an integrative review of published research studies and evaluation reports from programs
that distributed misoprostol at the community level for prevention of PPH at home births. We reviewed methods
and cadres involved in education of end-users, drug administration, distribution, and coverage, correct and
incorrect usage, and serious adverse events.
Results: Eighteen programs were identified; only seven reported all data of interest. Programs utilized a range of
strategies and timings for distributing misoprostol. Distribution rates were higher when misoprostol was distributed
at a home visit during late pregnancy (54.5-96.9%) or at birth (22.5-83.6%), compared to antenatal care (ANC)
distribution at any ANC visit (22.5-49.1%) or late ANC visit (21.0-26.7%). Coverage rates were highest when CHWs
and traditional birth attendants distributed misoprostol and lower when health workers/ANC providers distributed
the medication. The highest distribution and coverage rates were achieved by programs that allowed self-
administration. Seven women took misoprostol prior to delivery out of more than 12,000 women who were
followed-up. Facility birth rates increased in the three programs for which this information was available. Fifty-one
(51) maternal deaths were reported among 86,732 women taking misoprostol: 24 were attributed to perceived PPH;
none were directly attributed to use of misoprostol. Even if all deaths were attributable to PPH, the equivalent ratio
(59 maternal deaths/100,000 live births) is substantially lower than the reported maternal mortality ratio in any of
these countries.
Conclusions: Community-based programs for prevention of PPH at home birth using misoprostol can achieve high
distribution and use of the medication, using diverse program strategies. Coverage was greatest when misoprostol
was distributed by community health agents at home visits. Programs appear to be safe, with an extremely low
rate of ante- or intrapartum administration of the medication.
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The lifetime risk of dying from pregnancy or childbirth
ranges from about one in 39 in sub-Saharan Africa
to 1 in 3800 in developed countries [1]. Hemorrhage
continues to be one of the leading causes of maternal
death in developing countries, and the predominant
cause in Africa (34%) and Asia (31%) [2,3]. Postpartum
hemorrhage (PPH), defined as blood loss ≥ 500 mL,
occurs in approximately 6% of deliveries globally and
severe PPH (≥ 1000 mL) in an additional 1.8%, with
wide variation across regions of the world [4].
Various high-impact medical interventions effectively
prevent PPH. Active management of the third stage of
labor, using oxytocin as the preferred uterotonic, is
prominent among them [5,6]. Administration of oxyto-
cin, however, requires the assistance of a skilled birth at-
tendant (SBA), and therefore is not available to women
experiencing unattended home births, either by choice,
lack of access to SBAs [7,8], or due to gender and wealth
disparities [9-11].
Misoprostol, an oral prostaglandin E1 analogue that
can be administered immediately following delivery,
offers an important alternative for PPH prevention in
low-resource settings and at home births, where oxyto-
cin is not available or where its use is not feasible.
Misoprostol requires no injection supplies or skilled
provider for administration. Misoprostol does not need
refrigeration and can therefore be stored and provided
where there is no electricity. These factors enable
programs for the prevention of PPH using misoprostol
to potentially achieve high coverage and use, particu-
larly by women who reside at a distance from a health
facility [12-15].
Compelling evidence has emerged to demonstrate that
misoprostol is both safe and effective for this indication
[16-19]. This body of evidence led the World Health
Organization (WHO) to amend its model list of essential
medicines in March 2011 to include misoprostol for the
prevention of PPH in settings “where oxytocin is not
available or cannot be safely used” [20], although some
have expressed concern about this decision [21].
Recently published studies have additionally concluded
that the drug can be safely used at the community level
through either administration by health providers [22]
or distribution by community health workers (CHWs)
(including traditional birth attendants [TBAs]) directly
to pregnant women for self-administration at home
[15,23,24]. Sutherland et al. [25] noted that this inter-
vention is particularly cost effective. Rajbhandari et al.
[23] concluded that the largest gains in protection
against PPH were realized by the poor, the illiterate, and
those living in remote areas.
The 2012 WHO guidelines for the prevention and man-
agement of PPH [26] have included a recommendation forthe administration of misoprostol by CHWs for the
prevention of PPH. The guidelines also state that, to
date, there is insufficient evidence to recommend the
advanced distribution of misoprostol to women for self-
administration immediately after birth. A recent Cochrane
review [27] noted the need for additional information
concerning the feasibility of misoprostol reaching the end
user (coverage), patient outcomes after use, adverse effects
from misuse, and outcomes useful to policy makers, such
as resource utilization. The authors of that review further
urge the international community to take action to trans-
late the research evidence about the benefits of using oral
misoprostol for PPH prevention into community-based
research focused on the outstanding questions about
community-based distribution [28].
This integrative review of the literature was therefore
undertaken to synthesize the broad array of implemen-
tation experiences and research trials (collectively called
“programs”) that have used misoprostol for PPH
prevention during home births. The objectives of this
integrative review are 1) to describe qualitatively the
program strategies for distributing and administering
misoprostol for PPH prevention during home birth; and
2) where possible, quantitatively summarize the appar-
ent success of these approaches by determining the
rates of distribution, coverage (consumption by the tar-
get population), correct use, and serious adverse events
associated with different distribution and administration
methods. We also present additional data such as edu-
cation methods and the influence that community-
based distribution and use of misoprostol may have had
on the trend of facility-based birth. Our selection of
data is intended to emphasize those elements that we
consider to be most critical to evaluating any program
using misoprostol for the prevention of PPH in home
births.
Methods
Protection of human subjects
This project was submitted to the Institutional Review
Board at the Johns Hopkins Bloomberg School of Public
Health, U.S.A. A notice of exempt approval was received.
Project data reflected in this article were de-identified by
the authors of the original reports from which information
was extracted.
Integrative review methodology
The integrative review is a comprehensive methodo-
logical approach that takes an expansive view of the type
of information that can be included: it considers both
qualitative or quantitative data as well as reports of both
experimental and non-experimental studies [29]. The
integrative review methodology widens the sampling
frame beyond the limits imposed by meta-analysis
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(which focus on a single question, and place highest value
on randomized clinical trials) [30]. The major limitation of
integrative reviews is the potential for bias from its inclu-
sion of non-peer-reviewed information. In addition, be-
cause integrative reviews combine information from both
controlled studies and less structured data sources, fewer
analytical tools are available to compare and synthesize
data, leading to more qualified conclusions.
Literature review strategy
We searched PubMed for all peer-reviewed literature
published prior to December 1, 2012 using the
keywords “misoprostol” and “postpartum hemorrhage”
and either “home” or “community.” This information
was supplemented by a web-based search of the grey
literature, including non-peer-reviewed publications and
project reports using the terms above. We also conducted
a directed search of the websites of anticipated im-
plementing organizations, and made inquiries among pro-
fessional networks to identify unpublished information
from such programs.
Inclusion and exclusion criteria
Results from the searches and queries were first screened
by a single reviewer to identify literature concerning the
implementation of programs using misoprostol for the
prevention of PPH. Only literature that presented final,Peer-reviewed literature 
(PubMed search, no limits: misoprostol AND 
“postpartum hemorrhage” AND (home OR 
community)
50 results
26 results excluded on title/abstract review:
16 were policy or commentary
6  did not involve misoprostol alone or 
were not implementation studies (e.g. cost-
effectiveness)
1 involved misoprostol for a non-PPH use
3 were otherwise irrelevant
16 results excluded on full-text review:
8 did not use original data
2 did not use misoprostol at home births
6 did not present data corresponding to a 
majority of the extraction categories
8 peer-reviewed literature results 
included
Figure 1 Screening and Inclusion Process.original data regarding misoprostol use in home births
and that included data that corresponded to a majority of
the data elements discussed below was included for data
extraction. Information that was informally shared with
the study authors but that is not publicly available or avail-
able upon request to the authors in a written report was
excluded. The screening and exclusion process is depicted
in Figure 1.
Data extraction
A data extraction form was developed by all authors,
through an iterative process to identify all data elements
that were considered most critical to the review questions.
Data definitions that underpinned data extraction are
presented as Table 1.
Elements relating to program design and process
included: the timing and method(s) of distribution of
misoprostol; cadre(s) involved in the distribution; methods
of education of distributing cadres and end-users; the per-
son who ultimately administered the misoprostol; and
methods by which the misoprostol was tracked. Elements
relating to program outcomes included rates of distribu-
tion and coverage of the misoprostol, data on correct use
of the drug, serious adverse events (specifically including
the conduct of maternal death audits and/or verbal autop-
sies), and the effect on facility birth rates.
Data extraction from published studies or technical
reports was conducted by two independent reviewers.Grey literature 
(Directed search of websites and inquiries 
within professional networks)
55 results
41 results excluded on summary review:
8 were policy or commentary
26 did not involve misoprostol alone or 
did not discuss implementation
3 involved misoprostol for a non-PPH 
use
4 were otherwise irrelevant
4 results excluded because there was no 
formally-reported data




Distribution Timing The time during pregnancy when misoprostol was given to study or program participants.
Distributing Cadre The cadre(s) of health workers responsible for giving misoprostol to women. This includes health care providers,
community health workers and other community health agents, such as traditional birth attendants or community drug
keepers.
Administration Method The method by which misoprostol was administered to the women at the time of use. Typically this was administration
by a health worker, administration by a community provider or self-administration by the woman or a family member.
Home Birth Rate The national or catchment-area rate of home births as reported in the publication or written report, or the calculated
proportion of home births in comparison study sites.
Administration Before Birth Misoprostol administration while the woman is still pregnant or prior to delivery.
Adverse Maternal
Outcomes
Adverse outcomes, including Maternal Death and Perceived PPH/Excessive Bleeding, that are severe and relevant to
misoprostol use and that are reported as occurring in a study or program participant who delivered at home and used
misoprostol.
Maternal Death Death within 24 hours of delivery reported as occurring in a study or program participant who delivered at home and
used misoprostol. Both total deaths and deaths attributed to PPH or excessive bleeding are reported.
Distribution Rate The proportion of pregnant women in the catchment area who received misoprostol for the prevention of PPH.
Coverage Rate The proportion of women who delivered at home in the catchment area (actual or estimated) who used misoprostol
for the prevention of PPH.
Perceived PPH/Excessive
Bleeding
Women’s perception of excessive postpartum bleeding or measured postpartum blood loss. A specified tool was used
in some programs to measure blood loss and inform the threshold for referral.
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dependent data extraction processes was then compared
between the two reviewers and confirmed by a third. In
all cases in which there was a discrepancy of data, the
issue was discussed and resolved among the authors,
adhering to the wording of the original reports as closely
as possible.
Information provided verbally by representatives of
agencies contacted for information was cross-checked
against information about the program that was available
in written form. The documented information was al-
ways selected as the source of verified data. No new or
secondary analysis of undocumented data was performed
for this review.
Some of the information obtained concerned programs
implemented by the employing agencies of this review’s
authors. In these cases an independent third party
reviewed all data extractions, and resolved any instances
of data variance.
Data analysis
Rates and rate ranges were computed using Microsoft
ExcelW. This approach was most appropriate to the
nature of the data, for which traditional meta-analysis
was not applicable.
Calculations of distribution (receipt) and coverage (con-
sumption) rates required actual or estimated numbers of
potential beneficiaries (for distribution, all pregnant
women, and for coverage, women delivering at home)
within the areas or districts forming the programs’
respective “catchment areas.” For the distribution rate, the
number of pregnant women in the catchment area during
the period of the intervention could be estimated bymultiplying the population crude birth rate and the
program’s duration.
For the coverage rate, the number of pregnant women
delivering at home was estimated by multiplying the
number of pregnant women in the catchment area by
the program’s home birth rate. Often, the number of
women taking misoprostol at a home birth was reported
for only a subset of women from the study population
who were followed up after delivery.
Although some programs reported several forms of
incorrect use, the consumption of misoprostol prior to
birth was considered most important and was reported for
any program that provided this information. Analysis of
adverse maternal outcomes included PPH or perceived ex-
cessive bleeding [31,32], maternal death, and other serious
morbidities specifically reported by the programs. The
definitions and categories used by the original authors
were used wherever possible (see Table 1), so as to prevent
misinterpretation or underreporting. Additional informa-
tion about considerations made in selected computations
is provided as footnotes to the respective tables, for the
purpose of clarity and transparency.
Results
This integrative review identified 18 programs that used
misoprostol for PPH prevention among women who
experienced childbirth at home (Table 2). Eight of these
programs were studies with experimental or quasi-
experimental designs that included comparison of
misoprostol with placebo or another uterotonic. Five
were operations research projects, and five were field
interventions that provided misoprostol as part of a
pilot or full program approach, without intention to




Design and scope Home birth rate (for region







Number of women taking
misoprostol (a indicates overall;




Afghanistan [24]* Study using nonrandomized experimental control design
in 2 districts
80.1% 2039 13501 Self
Bangladesh [33] Operations research project in 6 districts 87% 118,594 enrolled; 77,337
delivered, of whom 53,897
received CDK2
46,561a 1893b Self and TBA
Bangladesh [14]*3 Study using quasi-experimental design in 2 districts 85%** 1009 884 CHW
Bangladesh [34] Pilot project in 1 district 85%** 19,497 9228 Self
Ethiopia [13]* Study using quasi-experimental design in 1 area 97% 500 485 TBA
Gambia [35]* Study using randomized controlled design in 1 district 72% 630 630 TBA
Ghana [36] Pilot project in 4 districts 37.5% 5345 1261b Self
India [22]* Study using randomized controlled design in 1 district 45.2% 812 809 SBA
Indonesia [37] Study using nonrandomized experimental design in 2
districts
48% 1322 999 Self
Kenya [38] Pilot project in 2 districts 38.7% 3844 1084b Self and SBA
Mozambique [39] Operations research project in 4 districts, with each of 3
sites using a different distribution strategy: 1) late ANC
only, 2) TBA at birth, 3) a combination of late ANC and
TBA at birth
35.3% 11,927 4781b Self and/or TBA
Nepal [23]* Operations research project in 1 district 89.1% 18,761 13,969a 435b Self
Nigeria [40] Operations research project in 1 state 95% 1875 1421b TBA
Pakistan [15]* Study using randomized controlled design in 1 province 65%** 534 533 TBA
Pakistan [41]*4 Study using quasi-experimental design in 2 districts 61% 872 678 TBA
Tanzania [42] Operations research project in 4 districts 30.8% 12,511 1826b Self
Zambia [43] Pilot project in 5 districts 59.9% 5574 233b Self
Zambia [44] Pilot project in 10 districts 71% (for rural areas)** 31,315 Not reported Self and TBA
1 Administration Before Birth and Adverse Maternal Outcomes were reported for all 1421 women in the intervention group who took misoprostol, regardless of the place of delivery, but for consistency with other
studies and programs (and because there was no indication to the contrary), we have assumed, particularly for the adverse outcomes reported in Table 6, that any such outcomes occurred only in those 1350 women
taking misoprostol for home births.
2 Misoprostol included in CDK. The kits used by these programs included gloves, soap, a blood loss measurement mat [31,32,45] and other materials recommended for use by women who delivered at home.
3 Dose of misoprostol used was 400 μg (two tablets).





























Any ANC visit (>12 weeks) 4 22.2
Late pregnancy ANC visit (>28 weeks) 3 16.7
Late pregnancy home visit
(28–32 weeks)
5 27.8




Health workers2/ANC providers 7 38.9








1 Includes female community health volunteers in Nepal and community-
based lady health workers in Population Council’s Pakistan program.
2 Includes auxiliary nurse midwives in India.
3 One program with 99.6% CHW distribution and only 0.4% TBA distribution
was considered to be CHW distribution only.
4 This category also includes two types of semi-skilled health workers: auxiliary
nurse midwives in India and community midwives in Kenya.
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prevention, but, rather, to document the operational
and health-related outcomes of the program’s chosen
implementation methods.
All but one of the programs included in this review
either explicitly mentioned using a dose of 600 μg
misoprostol, which is commonly manufactured as three
tablets of 200 μg each, or mentioned using “three
tablets” and therefore presumably used a dose of
600 μg, the WHO currently recommended dosage [46].
One program used a dose of 400 μg only [14].
Thirteen of the 18 programs described their user edu-
cation methods in their reports. The programs used a
variety of strategies to provide information, education
and communication to women and their families about
the purpose and proper use of misoprostol, including
individual meetings, group meetings, print media, and
radio messages. Most programs emphasized the import-
ance of delivering in a health facility as one of the key
messages.
Nine programs described information on stock-outs
and methods used to avoid them. All 18 specified the
number of doses distributed. Accounting methods
included periodic meetings among program staff (n = 8;
44.4%), stock monitoring by hand count (n = 6; 33.3%),
and accounting for the voluntary return of unused drugs
(n = 3; 16.7%).
Tables 3 and 4 depict the various times chosen by
programs to distribute misoprostol to women, the cadres
used to distribute the drug, and the individual(s) who
administered the drug. Four of 18 programs (22.2%)
distributed the drug earlier than 28 weeks of pregnancy.
Nine programs distributed misoprostol at the time of
home birth, two of which included the medication in
clean delivery kits (CDKs) [45].
Health workers (including ANC providers) and TBAs
were the most common distributors of the medication
(7 programs each). Six programs used CHWs, and two
used “other” community health personnel, such as family
planning field workers or community drug keepers, in
the distribution effort.
Self-administration (n = 11; 61.1%) and administration
by TBAs (n = 8; 44.4%) were the two most common
methods used for administration of the drug (Table 3).
Additional methods included administration by CHWs
and skilled or semi-skilled birth attendants.
Tables 4 and 5 illustrate the wide variation in the distri-
bution and coverage rates achieved among the 11
programs for which sufficient information was available.
Seven programs did not report sufficient information to
reliably calculate either of these rates. One program in
Mozambique used three different distribution strategies,
resulting in similar distribution rates regardless of whether
TBAs, ANC providers, or both, were the distributingcadre(s) (range of 21.0% to 26.7%); however, markedly
higher coverage rates were achieved with TBAs as the dis-
tributing cadre (73.5% compared to 16.2% for ANC only).
The unexpected similarity in distribution rates might be
explained by the fact that only a sub-sample of women
with follow-up data was included in the calculations from
ANC distribution sites, while the entire sample was
included in the calculations from TBA distribution sites.
Three programs attempted to assess whether there
was any change in the facility birth rate in the districts
in which misoprostol was distributed for home use. In
Afghanistan [24] and Zambia [43] comparison between
the intervention and control areas showed an increase of
3.3% and 13.8%, respectively, in facility birth rates in the
intervention areas. In Nepal [23] there was an increase
of 3.9% in the facility birth rates at the end of the inter-
vention, when compared to the beginning.
Table 6 presents the occurrence of adverse outcomes
when misoprostol was used for prevention of PPH at
home birth. Incorrect use of the drug (consumption
before the birth) occurred in seven cases across four
programs, among 12,615 users, for an overall rate of
0.06%. Many of the programs also reported instances
when the drug was incorrectly administered after deliv-
ery of the placenta or if fewer than the required number
of tablets had been taken.
Table 4 Distribution and coverage rates or rate ranges by distribution timing, distributing cadres and administration
method (for programs for which rates were calculable)
Distribution or administration feature
(multiple possible, and for this table, the 3







Any ANC visit 22.5–49.1% 16.8–65.9%
Late ANC visit 21.0–26.7% 16.2-35.9%
Home visit (late pregnancy) 54.5-96.6% 55.7-93.8%
At home birth 22.5-83.6% 16.8-73.5%
Distributing
cadre
Community health worker 54.5-96.6% 87.9-93.8%
Traditional birth attendant 25.9-86.5% 35.9-73.5%





Traditional birth attendant 25.9-86.5% 35.9-73.5%
Community health worker N/A N/A
Skilled birth attendant or
semi-skilled health worker 22.5% 16.8%
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the 86,732 women taking misoprostol for home birth.
A total of 24 of these deaths were attributed to
perceived PPH or excessive bleeding. No deaths in the
18 programs reviewed were reported to be directly
attributed to use of misoprostol.
Program reports mention three cases of suspected
uterine rupture among women who took misoprostol
following delivery. The diagnosis cannot be confirmed in
any of these cases, given that the maternal audit
methods used by these programs were not described and
no autopsy was reported. The incidence of other adverse
outcomes requiring hospital transfer was equal to or less
than one third of 1% among 17 programs reporting on
serious adverse events.
Discussion
This integrative review shows a range of implementation
approaches, data collection procedures, and documenta-
tion approaches in programs for prevention of PPH
at home birth using misoprostol. We recognize the
limitations in comparing programs and drawing summary
conclusions from different implementation models and
data reporting practices, but we believe that a sufficient
number of community-level misoprostol programs have
been attempted to date to render discussion and interpret-
ation of their methods and outcomes timely and appropri-
ate. The nature and quality of the data, a majority of
which was extracted from non-peer-reviewed project
reports, restricts the statistical methods that could be used
in data analysis, and requires the following caveats
regarding generalizability.The information that we sought to retrieve for purposes
of this integrative review was not necessarily a component
of the program monitoring plans for all programs, and,
even if collected, was not necessarily reported or reported
in a comparable manner. As a result, there are missing or
assumed data for some variables of interest. For example,
a common definition of PPH as an adverse event was not
present in all reports, and reports that used the term ex-
cessive bleeding were assumed to be referring to perceived
PPH. Explicit mention of PPH was itself absent in one
report.
Additionally, this review might be biased toward more
favorable results. In addition to selective data extraction
from included programs, programs that were excluded
from this review because of substantial missing data might
have contained unfavorable results that the implementing
organizations chose not to share with the public, although
this is unlikely.
It is interesting to note that a substantial number of
programs did not collect or report sufficient data to es-
timate their distribution or coverage rates. Given that
misoprostol for home birth is a strategy to achieve
greater protection from PPH – regardless of location of
birth – we anticipated that these data would have been
more readily available.
We were particularly cautious in estimating the rates of
distribution and coverage of misoprostol because we
understand that most programs were not attempting to
reach all pregnant women within an intervention area and
did not follow up with all women who received
misoprostol prior to delivery. Estimations were based on
available data and assumptions regarding population or
sample data. The heterogeneity of program methodologies
Table 6 Adverse outcomes
Outcomes N of occurrences in
programs reporting1






73 (12,615) 0.06% (0%–0.23%)
Maternal deaths




24 (86,732) 0.03% (0.00%–0.16%)
Perceived PPH/
excessive bleeding





27 (86,732) 0.03% (0%–0.3%)
1 For Administration Before Birth and Perceived PPH/Excessive Bleeding, only
those programs reporting comparable data for the specific category have
been included in the calculation. For Maternal Deaths and other adverse
outcomes requiring hospital referral, because of the severity of these
outcomes, it has been assumed that if a study or program reported data on at
least one of these outcomes and did not mention other outcomes, the other
outcomes did not occur.
2 Some programs only collected data on these outcomes for a subsample of
women taking misoprostol for home births, as noted in Table 2. The
Administration Before Birth total includes subsample numbers if both overall
and subsample numbers are available. The Adverse Maternal Outcomes data,
however, includes overall numbers wherever available because the presence
of community information sources makes it likely that such outcomes would
be known and noted for the entire home-birth misoprostol population.
3 This includes one inferred occurrence from information that one woman in
the Ghana program took misoprostol at the incorrect time and not after
delivery of the placenta.
4 Such outcomes were enumerated in 2 programs. In one program, the
outcomes were reported as including “retained placenta, postpartum
eclampsia, severe lower abdominal pain, and lack of typical postpartum
bleeding.” In the other program, the outcome enumerated was “severe
postpartum anaemia.”
Table 5 Misoprostol distribution and coverage rates
(for programs reporting)
Country Distribution rate (%) Coverage rate (%)
Afghanistan [24] 96.6 93.8
Bangladesh [34] 66.5 55.7
Ghana [36] 49.1 65.9
Indonesia [37] 54.5 87.9
Kenya [38] 22.5 16.8
Mozambique [39]1
TBA only 25.9 73.5
ANC only 21.0 16.2
TBA and ANC 26.7 35.9
Nepal [23] 72.2 Insufficient information
Nigeria [40] 83.6 Insufficient information
Pakistan [41] 86.5 Insufficient information
Tanzania [42] 26.3 29.3
Zambia [43] 40.3 Insufficient information
1 This program had a different distribution strategy at each of three different
sites. To distinguish among approaches, results are presented for each
strategy separately.
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fore we present rate ranges. Footnotes in the tables
present additional information about calculations. Actual
distribution and coverage rates at home births could be
higher than those we calculated and reported.
We present misoprostol distribution separate from its
coverage because fewer women might consume the drug
than those who receive it. Consumption, or coverage,
presents a more accurate measure of program effective-
ness than distribution because it reflects both successful
distribution as well as effective counseling to the woman,
her family, and any involved providers.
No particular timing was predominant among programs
that distributed misoprostol prior to birth (n = 12), with
programs using early, late, or unrestricted distribution
timing. However, the range of distribution rates to the tar-
get population of pregnant women was lower for late
ANC visit distribution compared to distribution at any
ANC visit.
Programs that allowed distribution by CHWs and dur-
ing home visits achieved greatest distribution and cover-
age, potentially more than double the coverage achieved
by programs with distribution by health workers or as a
part of ANC services. Distribution of the drug by other
types of community-based workers also appeared to allow
high distribution and coverage rates, in the very few
programs for which this strategy is reported. This suggests
that home-based distribution approaches, with relatively
low-skilled providers, either singly or combined with
facility-based approaches, can achieve high rates of distri-
bution to the target population. This is potentially due to
the pressures that health workers are under during theirroutine work and the difficulty that comes from adding
additional tasks. CHWs, on the other hand, might be able
to add this service to their work more easily, and likely
have multiple opportunities to see a woman. As well,
home-visit distribution by CHWs is primarily dependent
on the actions of the worker, not the health-seeking behav-
ior of the woman, whereas traditional ANC in a facility
can only occur if the woman presents to the facility for
care.
Eleven programs distributed misoprostol to women
prior to birth. Several of these programs also allowed for
administration to the woman at the time of birth at home,
likely enhancing their overall distribution and coverage
rates. The rates of ANC and skilled birth attendance are
low in these program communities, so the programs stra-
tegically chose to provide women with protection against
PPH even in situations where their births were not
attended by SBAs.
Another area of great concern among maternal health
advocates globally is whether a strategy of provision of
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increasing facility birth rates. Only three of the 18
programs reviewed tracked this indicator. In none of
those did the facility-based birth rate decline; indeed, the
rate appeared to increase, although the calculation
methods differ and the data do not conclusively support
an attribution of changes to the programs themselves.
Those three programs appeared to put a high value on
education of the woman and her family regarding the
importance of skilled attendance at birth, the dangers of
PPH, and the use of misoprostol only for the situation
where a woman is unable to achieve her plan of a
facility-based birth.
The number of cases in which women took misoprostol
prior to delivery is reassuringly low, as this is one of the
areas of greatest concern for the international public
health community. Administration before birth occurred
in only seven cases out of more than 12,000 women who
were followed up (0.06%). One case was due to a woman
taking the dose before delivery of a second twin. The sec-
ond twin delivered normally without complication. An-
other case was a woman responding to a domestic dispute
with intention of self-harm. She was immediately identi-
fied and referred to a nearby facility where she delivered
normally within 12 hours. Authors reporting on the
Ghana program stated that there were four women who
took the drug at the wrong time, three of whom took the
drug after delivery of the placenta. We therefore assume
that the fourth case was that of a woman who took the
drug prior to birth, but no further information is available
from the program description. Four cases occurred in one
large program in Bangladesh for which there was no
specific information about circumstances or outcomes. It
is possible that there might be additional cases of adminis-
tration prior to the birth that were unreported, although
the likelihood of this is low, given the high profile of most
of these programs.
With such a low occurrence of premature administra-
tion, it is difficult to draw any meaningful distinctions
among the programs, each of which had various and
unique features in design. More of the cases of premature
administration occurred when the drug was distributed at
any ANC visit compared to ANC or home distribution
closer to the time of birth, and when distribution was by a
health worker or ANC provider compared to distribution
by a lay health worker.
All but one program made an attempt to identify and
record the number of maternal deaths in the program’s
target area, and specifically, the number of maternal
deaths that occurred among women who took miso-
prostol. Virtually every program that recorded the num-
ber of maternal deaths also noted the method(s) by
which the deaths were investigated. Investigations were
also commonly undertaken to verify accounts of reportsof excessive postpartum bleeding reported by women,
their family, or their birth attendants. Such rigorous
methods help ensure that such deaths can be more inde-
pendently reviewed and evaluated for any relationship to
either the drug or its method of distribution or adminis-
tration. It is reassuring that there were no cases of ma-
ternal death that were attributed to misoprostol across
the almost 87,000 women who took the drug as part of
these programs.
Conclusion
This integrative review has synthesized the available body
of information about completed programs using mis-
oprostol for prevention of PPH at home birth. The quan-
tity and comparable quality of available data are limited,
and the non-peer-reviewed sources of the majority of
these data restrict the rigor of the statistical approaches
used for data analysis. However, even given these
limitations, findings from this review should promote
understanding about the outcomes of various misoprostol
program approaches and begin to address outstanding
concerns by describing the outcomes of program
outreach.
Findings from this review of 18 independent programs
conducted in 14 low-resource countries qualitatively
demonstrate that it is possible to achieve high distribu-
tion and coverage of misoprostol especially when com-
munity health systems are engaged in the distribution
effort. Programs that distributed misoprostol at home
visits late in pregnancy or at the time of birth, as well as
those that used community-based personnel, appear to
achieve higher coverage than those that used formal
health workers and ANC distribution, either alone or in
combination with home distribution.
Self-administration by the woman and administration by
the TBA have been the most common methods of admin-
istration of the medication, and programs that used these
administration methods achieved higher coverage rates
than those that required skilled or semi-skilled birth
attendants for administration. Programs that educate
women and families for self-administration of misoprostol
appear to be safe, with an extremely low rate of erroneous
early administration.
While few programs provided data on changes in facil-
ity birth rates, and none permit attribution of those
changes directly to the misoprostol distribution efforts,
community-based programs using misoprostol at home
births do not appear to work against national efforts to
increase facility birth rates. Future misoprostol programs
should be designed in a manner that ensures adequate
and comparable data collection regarding the key
features and outcomes discussed in this review, namely,
distribution, coverage, correct use, education, and effect
on facility birth rates.
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